Model-Based Drug Development for Diabetes Treatment

Guest Editors:

Dr. Michele Schiavon
Department of Information Engineering, University of Padova, 35131 Padova, Italy

Dr. Roberto Visentin
Department of Information Engineering, University of Padova, 35131 Padova, Italy

Deadline for manuscript submissions:
closed (20 August 2023)

Message from the Guest Editors

This Special Issue invites research and review articles on the use of mathematical modeling and simulation as a tool for drug development and testing in the field of diabetes treatment. Articles based on in vitro/preclinical to clinical data exploiting modeling and simulation tools for designing first-in-human trials, predicting drug-to-drug interactions, quantifying factors affecting variability, as well as simulating new delivery systems, and therapeutic treatments and dosing regimens in the target populations of novel or repurpose drugs are some of the research areas that this Special Issue aims to include.

Special Issue

Editor-in-Chief

Prof. Dr. Patrick J. Sinko
Department of Pharmaceutics, Ernest Mario School of Pharmacy, Rutgers University, Piscataway, NJ 08854, USA

Message from the Editor-in-Chief

Pharmaceutics (ISSN 1999-4923) is an online open access journal on the science and technology of pharmaceutics and biopharmaceutics. The scientific community, the wider community and the general public have unlimited and free access to the content as soon as a paper is published; this open access to your research ensures your findings are shared with the widest possible audience. Please consider publishing your impressive work in this high quality journal. We would be pleased to welcome you as one of our authors.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.
High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.
Journal Rank: JCR - Q1 (*Pharmacology & Pharmacy*) / CiteScore - Q1 (*Pharmaceutical Science*)

Contact Us